Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
Daxor's ezBVA Lab Service Spearheads Growth and Broader Market Adoption
Daxor的ezBVA實驗室服務帶頭推動增長和更廣泛的市場採納
Oak Ridge, TN, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA) in three new facilities. Daxor's ezBVA lab service is a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company anticipates sustained accelerated sales growth during the rest of the year.
田納西州奧克嶺,2024年8月5日(全球新聞社) - Daxor公司 全球血容量測量技術領導者納斯達克股票代碼爲DXR的Daxor宣佈擴大三個新設施的血容量分析(BVA)。Daxor的ezBVA實驗室服務是一家先進的CLIA認證實驗室,可提供按需、次日的血容量分析結果。該公司預計在今年剩餘時間內將維持加速的銷售增長。
Recent sales wins include:
最近的銷售利潤包括:
- Leading full-service medical center in Georgia adopts Daxor's ezBVA Lab service.
- Second hospital, part of the largest non-profit health system in North Carolina, purchases a blood volume analyzer.
- Top-rated Central Florida hospital implements Daxor's ezBVA Lab service.
- 佐治亞州領先的全方位醫療中心採用Daxor的ezBVA實驗室服務。
- 北卡羅來納州最大的非營利性健康系統下屬的第二家醫院購買了血容量分析儀。
- 位於佛羅里達州中心評價最高的醫院採用Daxor的ezBVA實驗室服務。
"Providing efficient and effective options to implement our diagnostic solution empowers healthcare facilities to meet the dual challenges of enhancing patient care and managing expenses," said Jean Oertel, Sr. VP Commercialization and Customer Experience. "The increase in adoption of our blood volume analysis technology underscores its critical impact in advancing treatment effectiveness for fluid management and is driving further sales growth for the company."
Jean Oertel,高級副總裁商業化和客戶體驗表示:「提供高效、有效的選項來實施我們的診斷方案,使醫療保健設施能夠應對加強患者護理和管理費用的雙重挑戰。我們的血容量分析技術的採用增加,突顯了它在推進液體管理的治療效果方面的關鍵影響,併爲公司帶來進一步的銷售增長。」
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
關於Daxor公司
Daxor Corporation(納斯達克股票代碼爲DXR)是全球血容量測量技術領域的領導者,專注於血容量測試創新。我們開發並銷售BVA-100(血容量分析儀),這是唯一獲得FDA批准的診斷性血液測試,可提供與患者特定規範相比的安全、準確、客觀的血容量狀態和組成的量化。在美國領先的醫院中心已經進行了65000多項測試,在廣泛的外科和醫學病症中提高了醫院的性能指標,包括在心力衰竭和重症護理中顯著降低死亡率和再入院率。Daxor在心力衰竭治療方面有幾項正在進行的試驗,並在與美國國家衛生研究院(NIH)的支持下開展一項合同開發分析儀,以改善作戰傷員護理。Daxor的使命是通過血容量分析使流體管理達到最佳狀態。Daxor的願景是爲所有人提供最佳的血容量。有關更多信息,請訪問我們的網站。 Daxor.com。註冊以接收關於Daxor的創新技術的新聞這裏.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
前瞻性聲明
本新聞稿中的某些聲明可能包括1995年《私人證券訴訟改革法》中的前瞻性聲明,包括但不限於有關僱用銷售人員和擴大我們分銷渠道的影響的聲明。前瞻性聲明是基於當前期望和假設的未來事件的預測、投射和其他聲明,因此受到風險和不確定性的影響。許多因素可能導致本新聞稿中前瞻性聲明的實際未來事件與所述的前瞻性聲明不同,包括但不限於與我們的後市臨床數據收集活動相關的風險、我們的產品對患者的益處、我們對產品開發和商業化努力的期望、我們的產品市場和醫生接受度的提高、潛在的競爭產品提供、知識產權保護、FDA監管行動、我們整合已收購的業務的能力,我們的期望關於與收購企業預期的協同效應和好處,以及我們在SEC提交的文件中描述的其他風險和不確定性。前瞻性聲明僅適用於其作爲之日的情況。Daxor並不承擔公開更新或修訂任何前瞻性聲明的任何義務,無論是因爲新信息、未來事件還是其他原因。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
投資者關係聯繫人:
Bret Shapiro
高級合夥人,CORE IR Bret Shapiro
1-516-222-2560
brets@coreir.com